Pierrel Research is proud to announce that the ATOLL trial results have been published on The Lancet
the ATOLL trial results have been published on The Lancet, Volume 378, Issue 9792, Pages 693 - 703, 20 August 2011.
The ATOLL trial (Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial) has been realized with the support of “la Recherche Clinique, Assistance Publique-Hôpitaux de Paris” and Sanofi-Aventis.
Pierrel Research was in charge of the overall management of the electronic case report form (eCRF), all connected activities and the database management until the end of the study, and also successfully supported the conductance of this investigator initiated research project in Austria, Germany and the United States.
“We are very happy about this important publication on The Lancet considering that data quality is of special relevance in clinical trials – and a key point of assessing excellence for this journal. This confirms once more Pierrel Research’s extensive and documented expertise in the management of data coming from international clinical trials” remarked Dr. Luigi Visani, Chairman and CEO of Pierrel Research International AG.“